Sickle cell disease is one of the world's most prevalent genetic diseases. Major advances have been made in understanding the disease, paving the way for new and effective treatments. Neonatal screening is developing in many countries, resulting in early prevention of infections and improved parental education. New preventive treatments for vaso-occlusive crises and chronic anemia are now available.

In Kisumu, 32 out of 100 children born annually have SCD. This causes a significant burden on caregivers and families leading to both productivity and financial losses.

Kisumu County has been undertaking newborn screening for the last two years at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH), this has been a notable step in the effort towards the management of sickle cell.

Data from several hospitals in Kisumu shows that on average a sickle cell client suffers 5 episodes of crises annually and 5-10 days of hospitalization per episode has a big impact on the caregivers and family.

Though Hydroxyurea has proven clinical efficacy in preventing pain and vaso-occlusive events. Cure of the disease is now possible thanks to hematopoietic stem cell transplant and gene therapy.

Nevertheless, life expectancy and quality of life remain significantly degraded for the majority of patients. Access to safe transfusion and hydroxyurea is still limited in many countries. Education must be intensified; psychological and social support is needed.

The International conference in Kisumu will feature high-level scientific presentations, combined with patient testimonies and workshops.

Some of the conversations already slated in the experience that JOOTRH has had with neonatal screening for the last two years, born marrow transplant in a case of Nairobi West Hospital, SCD, and reproductive health, policy and public health in SCD, the prevalence of depression   amongst teenage warriors,

In recognition of the changing landscape for the management of Haemoglobinopathies. We are fully aware of the fact these new developments bring with them complex issues in decision-making for patients and their families and the challenge of access to therapies It is therefore necessary to provide the platform for service providers, service users, and policy-makers to engage in honest discussion to develop strategies for efficient and effective interventions across the world. Our constituency is every patient everywhere and, in all circumstances, to improve outcomes and increase access.

This year will discuss:

• The role of the private sector in SCD and hemophilia management and the use of rifaximin in resource-limited countries for prevention of sickle cell crises.
• SCD in diverse clinical landscapes and the use of a registry for managing sickle cell.
• Innovations in SCD.
• Comprehensive approaches to SCD management.

Abstract Submission along with Registration is now open to allow time for greater participation across the world.

Looking forward to seeing you soon!

For those who cannot attend in person, many of our convention components will be offered virtually. Convention registration is now open!